Thomas Köhnke

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML

Sascha Haubner, Fabiana Perna, Thomas Köhnke et al. · Leukemia · 2018 · 311 citations · Full text

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

Christina Krupka, Peter Kufer, Roman Kischel et al. · Leukemia · 2015 · 239 citations

Autoimmune Disease, Immunology, Immunologic Mechanism +8

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

Haijiao Zhang, Yusuke Nakauchi, Thomas Köhnke et al. · Nature Cancer · 2020 · 200 citations · Full text

Hematological Malignancy, Oncology, Medicine +12

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Christina Krupka, Peter Kufer, Roman Kischel et al. · Blood · 2013 · 199 citations

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

Thomas Köhnke, Christina Krupka, Johanna Tischer et al. · Journal of Hematology & Oncology · 2015 · 173 citations · Full text